Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald

Johnson & Johnson (NYSE:JNJGet Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, Benzinga reports. They currently have a $215.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 36.09% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Barclays boosted their price objective on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 12th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $176.14.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Stock Down 0.1 %

NYSE:JNJ opened at $157.98 on Tuesday. The firm has a market capitalization of $380.30 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. The stock has a 50 day moving average of $158.20 and a 200-day moving average of $159.04. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business’s revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.35 earnings per share. Analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in shares of Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its stake in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after buying an additional 82,429 shares during the period. AMI Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after buying an additional 1,475 shares during the period. Equitable Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after buying an additional 2,119 shares during the period. Finally, USS Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after buying an additional 20,528 shares during the period. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.